News and Trends 2 Jun 2025 Top biotech deals in May 2025 …to combine this molecule with Biogen’s drug delivery platform to target diseases that affect the central nervous system (CNS). In exchange, the American startup will receive $16 million upfront and… June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018 A New Biotech Hopes to Bring Us the Next Generation of Rare Metabolic Disorder Drugs …on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.” TiVenture’s managing… February 20, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? …years, or even a lifetime. When this happens, the disease is allowed to spread, potentially reaching the joints, heart and central nervous system (CNS), and can result in severe and… May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies …aspects of clinical drug development. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them. TrialSpark’s current therapeutic areas of focus include rheumatology, dermatology, CNS, and cardiometabolic diseases…. October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the… August 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 20 Jul 2023 Beyond Biotech podcast 55: Inflammasomes …meaningful reductions. Neurofilament light chain (NfL), exclusively synthesized in the central nervous system (CNS), decreased by approximately 25% over seven days in the most inflamed subject and by 13% on… July 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …be added to existing antibodies to generate a bispecific antibody (mAb²) that can cross the blood-brain barrier, as well as bind to specific targets within the CNS. Changes that occur… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NodThera first to show reduction in neuroinflammation with inflammasome inhibitor …previous observations and a range of inflammatory CSF biomarkers demonstrated meaningful reductions. Neurofilament light chain (NfL), exclusively synthesized in the central nervous system (CNS), decreased by approximately 25% over seven… July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low …RNA technology to treat central nervous system (CNS) disorders. Update (14/11/2017): Included the expected amount to be raised after ProQR issued a press release. Images via Puslatronik /Shutterstock; Yahoo Finance… November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Newron reports ‘striking’ schizophrenia study results …an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant… February 16, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy …another €6M a year. Among them are the leaders of the liver metabolism and CNS therapeutic areas, programs which will be eliminated. UniQure’s manufacturing will now be consolidated in its… November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Jan 2025 Top 19 most-performing biotech stocks of 2024 …central nervous system (CNS) to treat a range of neurological and psychiatric disorders. At the core of Bright Minds’ technology is its work on the serotonin 5-HT receptor family, particularly… January 27, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email